However, previous pharmacological strategies targetingretinoid isomerization of RPE65 were unsuccessful, mostly due to theinability to achieve a balance between beneficial and adverse effectsof therapies.45 To minimize the side effects,such as night blindness and dyschromatopsia, associated with the directblockage of 11cRAL production by RPE65 inhibitors, alternative strategieswere developed. The gene discussed is RPE65; the disease is night blindness.